Anciata Therapeutics Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Joint Venture

  • Latest Deal Amount
  • $34M

  • Investors
  • 2

Anciata Therapeutics General Information

Description

Operator of a special purpose enterprise intended to advance an oral therapeutic candidate to clinical proof of concept for the treatment of autoimmune disorders. The company offers an orally administered therapeutic candidate developed for targeted clinical evaluation, enabling patients with autoimmune disorders access to an additional treatment option.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anciata Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Joint Venture 10-Apr-2025 $34M Completed Startup
To view Anciata Therapeutics’s complete valuation and funding history, request access »

Anciata Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cellestia VC-Backed Company Minority
TVM Capital Life Science Venture Capital Minority
To view Anciata Therapeutics’s complete investors history, request access »

Anciata Therapeutics FAQs

  • When was Anciata Therapeutics founded?

    Anciata Therapeutics was founded in 2025.

  • Where is Anciata Therapeutics headquartered?

    Anciata Therapeutics is headquartered in Basel, Switzerland.

  • What industry is Anciata Therapeutics in?

    Anciata Therapeutics’s primary industry is Drug Discovery.

  • Is Anciata Therapeutics a private or public company?

    Anciata Therapeutics is a Private company.

  • What is Anciata Therapeutics’s current revenue?

    The current revenue for Anciata Therapeutics is .

  • Who are Anciata Therapeutics’s investors?

    Cellestia and TVM Capital Life Science have invested in Anciata Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process